CClinicalTrials.gg
TerminatedNCT05244915Updated Jan 6, 2025

A Supportive Care Intervention for Older Caregivers of Older Adults with Advanced Cancer

An interventional study of Experimental (Delphi Surveys) and Experimental (Focus Groups) in Cancer, sponsored by University of Rochester. Terminated at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by University of Rochester · Not applicable, Interventional, and Supportive care

Why this study was terminated
Study has been closed to accrual earlier than anticipated and will not resume.
Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

This project assesses the feasibility of utilizing the geriatric assessment as a tool to identify distressed older caregivers of older adults with cancer. The investigator will engage key stakeholders including older caregivers of older adults with cancer, experts in geriatric oncology and primary care physicians to develop and pilot a supportive care intervention to improve outcomes in older caregivers.

Read the detailed description

Older caregivers of older adults with cancer (described here-on as "older caregivers") are at high risk for increased burden and negative physical and psychological outcomes. Despite this, identification of older caregivers at risk for burden remains a challenge and evaluation of supportive care interventions and guidelines for this population remains limited. Health outcomes of older adults with cancer and their caregivers are inter-related and it is important to evaluate and support the health of both. The geriatric assessment (GA) is a valuable tool to evaluate health and age-related conditions (e.g., physical and cognitive function) of older adults with cancer and guide supportive care. Identifying older adults with age-related conditions can help to identify caregivers who are at increased risk for the negative impacts of caregiving. This project seeks to gather preliminary data on the health of older caregivers and to develop and pilot high priority supportive care interventions for this population. The investigator will examine the feasibility of utilizing the GA as a tool to identify distressed older caregivers. The investigator will engage key stakeholders including, older caregivers and older adults with cancer, experts in geriatric oncology and primary care physicians to develop and pilot a supportive care intervention to improve outcomes in older caregivers.

02

Conditions studied

  • Cancer

Keywords

  • Cancer
  • Geriatric Assessment
03

In context

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria

  • Patient and caregiver be aged 65 or older
  • Patient with a diagnosis of solid tumor malignancy or lymphoma, any stage
  • Patients who have initiated a new line of treatment (surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy) OR are being considered for new line of treatment (surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy).
  • Patients and caregivers must be able to provide informed consent, or if it is determined that they do not have decision-making capacity, a patient-designated health care proxy must sign consent per institutional University of Rochester and Research Subject Review Board policies on consent for incapacitated/decisionally impaired subjects.

Patient Exclusion Criteria

  • Patient or caregiver is less than 65 years of age
  • Patient and caregivers who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy available to sign consent.

Caregiver Inclusion Criteria

  • Caregivers enrolled in phase I
  • Patient and caregiver have completed a GA

Caregiver Exclusion Criteria

  • Patient and caregiver have not completed a GA

Stakeholder Inclusion Criteria

  • Member of SCOREboard Community Advisory Board
  • Aged 65 years or older
  • Has been a family member, partner, friend or caregiver to an older adult with cancer

Stakeholder Exclusion Criteria • None

Geriatric Oncology Expert Inclusion Criteria

  • Members of the Cancer and Aging Research Group
  • Primary care physicians who care for older adults

Geriatric Oncology Expert Exclusion Criteria

  • None
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Experimental

    Participants will receive a geriatric assessment which consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on participant responses, tailored recommendations will be provided.

    Other: Experimental (Delphi Surveys) · Other: Experimental (Focus Groups) · Other: Qualitative interviews

Interventions

  • OtherExperimental (Delphi Surveys)

    The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.

  • OtherExperimental (Focus Groups)

    Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.

  • OtherQualitative interviews

    Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who enroll and complete the GA

    Percentage of participants who were approached, enrolled in the study and completed the GA will be determined.

    Time frame: 8 weeks per participant

  2. Time for caregivers to complete the GA

    Time to complete the GA per caregiver will be determined by summing the time to complete self-administered and clinic portions of GA.

    Time frame: 8 weeks per patient

  3. Caregiver satisfaction with completing the GA

    Caregivers will complete a questionnaire to assess satisfaction with completing the GA

    Time frame: 8 weeks per patient

Secondary outcomes

  1. Percentage of caregiver supportive care recommendations that are implemented by patient/caregiver physicians

    Caregivers will be surveyed to determined number and types of supportive care they received from their clinical providers compared to the supportive care recommendations that were provided to their clinical providers.

    Time frame: 4 weeks

07

Study locations

1 site
  • University of Rochester
    Rochester, New York 14642, United States
08

References and documents

Individual participant data

Plan to share: Yes — A complete and final study protocol will be made publicly available through the University of Rochester Cancer Center Community Oncology Research Program Research Base Protocol and Data Sharing Committee. The full protocol and data will be made publicly available no later than the publication date of the study findings from the final dataset. The protocol will include a detailed description of the study population, hypotheses tested, measurement and assessment information, data definitions and codes, and the analysis plan utilized. We will be collecting identifying information. The final dataset will be stripped of identifiers prior to release for sharing. Published papers will be made available in portable document format.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244915
Lead sponsor
University of Rochester
Responsible party
Sindhuja Kadambi (Senior Instructor - Department of Medicine , Hematology/Oncology (SMD), University of Rochester) — Principal investigator
First posted
Feb 17, 2022
Start date
Dec 7, 2021
Primary completion
Aug 11, 2023
Completion
Aug 11, 2023
Last update
Jan 6, 2025

Study contacts

Sindhuja Kadambi
principal investigator · Univ. of Rochester Wilmot Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion